AR and prostate carcinoma: Remarkably, 5 induces apoptosis in human prostate cancer 22Rv1 cells (31.3% ± 8.2% apoptosis after treatment with 1 μM for 48 h), which are highly resistant to androgen receptor (AR)-targeted therapies due to a loss of the ligand-binding domain of the AR receptor [12].